Despite the positive trial results for pegozafermin, which would typically be a bullish signal for the stock, ETNB shares experienced a decline. This could be due to profit-taking, market conditions, or investor expectations already pricing in the trial's success. The short-term impact is negative due to the observed price drop, but the long-term outlook may still be positive if the drug progresses successfully through further clinical development and regulatory review.